[关键词]
[摘要]
目的 观察气滞胃痛颗粒联合莫沙必利治疗反流性食管炎的临床疗效。方法 选取焦作市第五人民医院于2016年1月—2017年2月收治的反流性食管炎患者116例,随机分为对照组和治疗组,每组各58例。对照组口服枸橼酸莫沙必利分散片,5 mg/次,3次/d;治疗组在对照组基础上口服气滞胃痛颗粒,5 g/次,3次/d。两组均持续治疗4周。观察两组患者临床疗效,比较治疗前后两组患者血浆胃动素(MOT)、血清胃泌素(GAS)、血清炎症因子水平和疼痛程度。结果 治疗后,对照组临床有效率为79.31%,显著低于治疗组的93.10%,两组比较差异具有统计学意义(P < 0.05)。治疗后,两组患者MOT、GAS含量显著升高(P < 0.05),且治疗组血浆MOT和血清GAS显著高于对照组(P < 0.05)。治疗后,两组患者肿瘤坏死因子-α(TNF-α)、IL-6水平显著低于治疗前(P < 0.05),且治疗组比对照组降低更显著(P < 0.05)。治疗后,两组患者视觉模拟评分法(VAS)显著降低(P < 0.05),且治疗组VAS评分显著低于对照组(P < 0.05)。结论 气滞胃痛颗粒联合莫沙必利可有效提高反流性食管炎患者血浆MOT和血清GAS,降低血清TNF-α和IL-6水平。
[Key word]
[Abstract]
Objective To observe the clinical efficacy of Qizhi Weitong Granules combined with mosapride in treatment of reflux esophagitis. Methods Patients (116 cases) with reflux esophagitis in Jiaozuo Jiaozuo Fifth People's Hospital from January 2016 to February 2017 were randomly divided into control and treatment groups, and each group had 58 cases. Patients in the control group were po administered with Mosapride Citrate Dispersible Tablets, 5 mg/time, three times daily. Patients in the treatment group were po administered with Qizhi Weitong Granules on the basis of the control group, 5 g/time, three times daily. Patients in two groups were treated for 4 week. After treatment, the clinical efficacy was evaluated, and the plasma MOT levels, serum GAS levels, serum inflammatory factor levels, degree of pain in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 79.31%, which was significantly lower than 93.10% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the MOT and GAS levels in two groups were significantly increased (P < 0.05), and the MOT and GAS levels in the treatment group were significantly higher than those in the control group (P < 0.05). After treatment, the TNF-α and IL-6 levels in two groups were significantly decreased (P < 0.05), and the serum inflammatory factor levels in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the VAS score in two groups was significantly decreased (P < 0.05), and the score in the treatment group was significantly lower than those in the control group (P < 0.05). Conclusion Qizhi Weitong Granules combined with mosapride in treatment of reflux esophagitis can effectively increase the plasma MOT and serum GAS levels, and reduce serum TNF-α and IL-6 levels.
[中图分类号]
[基金项目]
河南省医学科技攻关计划项目(201504022)